HMGB4 Antibody

What is HMGB4 and where is it predominantly expressed?

HMGB4 (High Mobility Group Box 4) is a member of the HMGB family of proteins that functions as a transcriptional repressor. Unlike its family members HMGB1-3, which have broader expression patterns, HMGB4 displays a highly restricted tissue distribution. It is highly expressed in adult mouse testis, with low expression in the brain, and is virtually undetectable in other tissues examined . In humans, HMGB4 expression has been detected primarily in the testis and prostate tissues through RT-PCR analysis, while being absent in other tissues, including uterine tissue . This tissue-specific expression pattern suggests a specialized role for HMGB4 in reproductive tissues, particularly in testicular function.

What applications are HMGB4 antibodies suitable for?

Commercial HMGB4 antibodies, such as the rabbit polyclonal antibody ab224500, have been validated for multiple experimental applications. These antibodies are particularly suitable for:

• Immunohistochemistry on paraffin-embedded tissues (IHC-P): The antibody has been successfully used to detect HMGB4 in human testicular tissues .

• Western blotting (WB): The antibody effectively recognizes HMGB4 protein in cell and tissue lysates, detecting a band at approximately 22 kDa, which corresponds to the predicted molecular weight of HMGB4 .

• Immunostaining analysis: Studies have shown that polyclonal antibodies against HMGB4 can be used to visualize the protein's subcellular localization, with strong nuclear staining observed in prostate epithelial, basal, and stromal cells .

The specificity of these antibodies has been demonstrated across these applications, making them reliable tools for investigating HMGB4 expression and localization.

How is the specificity of HMGB4 antibodies validated?

Validation of HMGB4 antibody specificity typically involves multiple complementary approaches to ensure accurate and reliable detection. The following methodologies are commonly employed:

• Western blot analysis using recombinant protein: The antibody should detect a single band of the expected molecular weight (approximately 22 kDa for native HMGB4) when tested against purified recombinant HMGB4 protein .

• Western blot comparison with positive and negative controls: Testing the antibody against cell lines that express HMGB4 (e.g., prostate cancer cell lines DU145 and LNCaP) alongside cell lines or tissues that do not express the protein. A specific antibody will show a single band in positive samples and no bands in negative samples .

• Mass spectrometry confirmation: For custom-generated antibodies, the immunogen (recombinant protein) can be validated through mass spectrometry to confirm its identity before immunization. For example, MALDI-TOF analysis identified specific precursor ion peaks (e.g., m/z 967.24, 1261.23, 1283.21, and 1370.26) that matched expected HMGB4 peptide fragments .

• Immunohistochemistry with tissue controls: Testing the antibody on tissues known to express HMGB4 (testis, prostate) and tissues known not to express it (e.g., uterine tissue) to confirm tissue-specific staining patterns that align with known expression profiles .

What is the recommended dilution range for HMGB4 antibodies in various applications?

Based on the available research, the following dilution ranges have been found effective for HMGB4 antibodies in different applications:

• Immunohistochemistry (IHC-P):

  • For paraffin-embedded human testis tissue, a dilution of 1/50 has been successfully used .

  • For prostate tissue samples, dilutions of 1:200 have produced specific nuclear staining .

• Western blotting (WB):

  • Effective dilutions range from 1/100 to 1/200 for detecting HMGB4 in cell lysates .

  • When analyzing recombinant HMGB4 protein expression in bacterial lysates, dilutions up to 1/200 have shown good specificity .

• ELISA:

  • For antibody titer determination, serial dilutions from 1/200 to 1/204,800 have been used, with some high-quality antibodies retaining reactivity at dilutions as high as 1:102,400 .

The optimal dilution may vary depending on the specific antibody, sample type, and detection method used, so preliminary titration experiments are recommended when working with new antibodies or sample types.

What is the subcellular localization pattern of HMGB4 detected using antibodies?

Immunohistochemical staining with HMGB4 antibodies has revealed a distinct subcellular localization pattern that differs from other HMGB family members. While proteins like HMGB1 function both as nuclear proteins and as secreted factors, HMGB4 appears to be predominantly localized within the nucleus.

In prostate tissue samples, strong immunostaining for HMGB4 has been observed in the nuclei of epithelial, basal, and stromal cells . In contrast, cytoplasmic staining in these same cells was notably weak . This nuclear-predominant localization pattern is consistent with HMGB4's proposed function as a transcriptional repressor.

The nuclear localization of HMGB4 suggests that its function is primarily restricted to nuclear processes such as transcription regulation, chromatin remodeling, or DNA binding, rather than extracellular signaling roles that have been described for HMGB1 .

How are polyclonal antibodies against HMGB4 generated and characterized?

Generation of high-quality polyclonal antibodies against HMGB4 involves a systematic process that includes antigen preparation, immunization, antibody purification, and comprehensive characterization. The methodology follows these key steps:

• Recombinant protein expression:

  • The full-length human HMGB4 cDNA is cloned into a prokaryotic expression vector (e.g., pET28a(+)) containing His6-tags .

  • The expression construct is transformed into E. coli BL21 (DE3) cells and protein expression is induced with IPTG (1 mM) .

  • The fusion protein typically has a molecular weight of approximately 28 kDa, which is higher than the theoretical molecular weight of HMGB4 (~22.4 kDa) due to the presence of fusion tags .

• Protein purification:

  • The recombinant protein is purified using affinity chromatography methods appropriate for the fusion tag .

  • The identity of the purified protein is confirmed through methods such as MS/MS analysis, where specific precursor ion peaks (e.g., m/z 967.24, 1261.23, 1283.21, and 1370.26) are identified that match expected HMGB4 peptide fragments .

• Immunization protocol:

  • New Zealand rabbits are immunized with the purified recombinant HMGB4 protein emulsified with Freund's complete adjuvant .

  • Booster immunizations are administered at 2-week intervals using Freund's incomplete adjuvant .

  • Serum is collected to monitor antibody titer development .

• Antibody purification:

  • Antiserum is collected and antibodies are purified using affinity chromatography, typically with a HiTrap Protein G column .

  • The column is equilibrated with phosphate buffer, washed, and antibodies are eluted with 0.15 M Gly-HCl (pH 2.5) followed by neutralization with Tris-HCl .

• Characterization and validation:

  • Antibody titer determination using ELISA, with titers as high as 1:102,400 reported for high-quality preparations .

  • Specificity testing using western blotting against recombinant protein and cell lysates known to express HMGB4 .

  • Application testing in immunohistochemistry using tissues with known HMGB4 expression patterns .

This methodical approach ensures the generation of highly specific polyclonal antibodies suitable for multiple research applications.

What techniques can be used to troubleshoot non-specific binding when using HMGB4 antibodies?

When encountering non-specific binding issues with HMGB4 antibodies, researchers can implement several troubleshooting strategies to improve specificity:

• Antibody titration:

  • Perform a dilution series to identify the optimal antibody concentration that maximizes specific signal while minimizing background. For Western blotting, starting dilutions of 1/100 to 1/500 are recommended, while for IHC-P, dilutions of 1/50 to 1/200 have proven effective for HMGB4 antibodies .

• Sample preparation optimization:

  • For Western blotting: Ensure complete protein denaturation by optimizing SDS-PAGE conditions, as HMGB4 is a nuclear protein that may require thorough denaturation for accurate size determination .

  • For IHC-P: Optimize antigen retrieval methods, as studies have successfully used microwave-based antigen retrieval with 0.01 M citrate buffer (pH 6.0) for HMGB4 detection in paraffin-embedded tissues .

• Blocking optimization:

  • Test different blocking reagents and concentrations. For HMGB4 detection in tissue sections, 10% normal goat serum has been effective .

  • Consider using protein-free blocking buffers if protein-based blockers might cross-react with the antibody.

• Cross-reactivity assessment:

  • Test the antibody against tissues or cells known not to express HMGB4 (negative controls) to identify potential cross-reactivity with related proteins. HMGB4 antibodies should show no signal in tissues like uterine tissue, which lacks HMGB4 expression .

  • Consider performing pre-absorption controls with recombinant HMGB4 protein to confirm specificity.

• Secondary antibody optimization:

  • Use secondary antibodies that have been cross-adsorbed against species that might cause cross-reactivity.

  • Optimize the secondary antibody dilution to reduce background while maintaining specific signal.

• Additional controls:

  • Include a primary antibody omission control (using PBS instead of primary antibody) to identify background due to the secondary antibody or detection system .

  • Consider using recombinant HMGB4-expressing cells as positive controls alongside wild-type cells in Western blot analysis .

How can HMGB4 antibodies be used to investigate differential expression in cancer tissues?

HMGB4 antibodies are valuable tools for investigating differential expression in cancer tissues, particularly in reproductive system cancers where HMGB4 is normally expressed. The following methodological approaches can be employed:

• Tissue microarray (TMA) analysis:

  • Prepare TMAs containing multiple cancer tissue samples alongside normal tissue controls.

  • Perform immunohistochemistry using validated HMGB4 antibodies at optimized dilutions (e.g., 1:200) .

  • Quantify staining intensity and subcellular localization patterns using digital image analysis.

  • Compare expression levels between cancer tissues and corresponding normal tissues.

• Western blot quantification:

  • Extract protein from cancer tissue samples and matched normal tissues.

  • Perform Western blotting using HMGB4 antibodies at appropriate dilutions (1/100-1/200) .

  • Quantify band intensity normalized to loading controls.

  • The expected size of HMGB4 (approximately 22 kDa) should be used to identify specific signals .

• Cell line model validation:

  • Use prostate cancer cell lines (e.g., DU145 and LNCaP) that have been shown to express HMGB4 .

  • Compare expression levels between cancer cell lines and normal epithelial cell lines.

  • Investigate subcellular localization through immunofluorescence or cell fractionation followed by Western blotting.

• Correlation with clinical parameters:

  • Analyze HMGB4 expression in relation to clinical data such as tumor grade, stage, and patient outcomes.

  • Perform statistical analysis to identify significant associations.

• Mechanistic studies:

  • Investigate the functional consequences of altered HMGB4 expression through gene knockdown or overexpression studies.

  • Use HMGB4 antibodies to confirm successful manipulation of protein levels.

  • Examine changes in cellular phenotypes such as proliferation, migration, or invasion.

It's important to note that while HMGB4 function appears to be restricted to the nucleus based on immunostaining patterns , analysis should include assessment of both nuclear and cytoplasmic expression to detect any cancer-associated mislocalization.

What are the methodological considerations for using HMGB4 antibodies in immunoprecipitation?

While the search results don't specifically discuss using HMGB4 antibodies for immunoprecipitation (IP), based on general principles and the information available about HMGB4 and its antibodies, the following methodological considerations would be important:

• Antibody selection and validation:

  • Select antibodies that have been validated for IP applications or have characteristics suggesting IP compatibility.

  • Test antibody affinity using ELISA or Western blotting before attempting IP. High-titer antibodies (such as those with titers up to 1:102,400 in ELISA) may be good candidates.

  • Consider using affinity-purified antibodies for improved specificity.

• Sample preparation:

  • For nuclear proteins like HMGB4, ensure proper nuclear extraction protocols are used, as HMGB4 shows strong nuclear localization with minimal cytoplasmic presence .

  • Use mild lysis conditions that preserve protein-protein interactions if studying HMGB4 complexes.

  • Include protease inhibitors (e.g., PMSF at 1 mM) to prevent protein degradation during sample preparation .

• IP protocol optimization:

  • Determine the optimal antibody-to-protein ratio. Start with 2-5 μg of antibody per 500 μg of protein lysate.

  • Consider pre-clearing lysates with Protein G beads to reduce non-specific binding.

  • For nuclear proteins like HMGB4, include DNase I treatment to reduce DNA-mediated precipitation.

  • Optimize wash conditions to reduce background while maintaining specific interactions.

• Controls:

  • Include a negative control using non-immune IgG from the same species as the HMGB4 antibody.

  • Use lysates from cells or tissues known not to express HMGB4 (e.g., uterine tissue) as negative controls.

  • Include input samples (pre-IP lysate) in Western blot analysis to confirm IP efficiency.

• Detection and validation:

  • Confirm successful IP by Western blotting using the same or different HMGB4 antibody.

  • If studying protein-protein interactions, consider mass spectrometry analysis of co-immunoprecipitated proteins.

  • Validate novel interactions through reciprocal IP or other interaction assays.

Given that HMGB4 functions as a transcriptional repressor , IP could be particularly valuable for identifying its binding partners in transcriptional regulation complexes, especially in testicular or prostate cells where it is predominantly expressed.

How can researchers distinguish between HMGB4 and other HMGB family members when using antibodies?

Distinguishing between HMGB4 and other HMGB family members (HMGB1, HMGB2, and HMGB3) requires careful antibody selection and experimental design. Here are methodological approaches to ensure specificity:

• Epitope selection for antibody generation:

  • Target regions with low sequence homology between HMGB family members. For example, commercially available antibodies like ab224500 target recombinant fragment protein within human HMGB4 from amino acid 50 to the C-terminus , which may contain sequences unique to HMGB4.

  • Consider generating custom antibodies against unique peptide sequences if available commercial antibodies show cross-reactivity.

• Antibody validation through multiple approaches:

  • Western blot analysis using recombinant proteins of all HMGB family members to assess cross-reactivity.

  • Testing on cell lines or tissues with known differential expression of HMGB family members. For instance, HMGB4 is primarily expressed in testis and prostate , while other HMGB proteins have broader expression patterns.

  • Knockdown validation using siRNA or CRISPR-Cas9 targeting specific HMGB family members to confirm antibody specificity.

• Tissue distribution analysis:

  • Leverage the unique tissue distribution pattern of HMGB4, which is predominantly expressed in testis and prostate, while other HMGB proteins are more widely expressed .

  • Use tissues known to express other HMGB proteins but not HMGB4 (e.g., uterine tissue) as negative controls for HMGB4 staining .

• Molecular weight discrimination:

  • HMGB4 has a predicted molecular weight of approximately 22 kDa , which can help distinguish it from other HMGB proteins if there are size differences.

  • Use high-resolution SDS-PAGE to separate closely sized HMGB proteins.

• Subcellular localization patterns:

  • HMGB4 has been shown to have strong nuclear localization with weak cytoplasmic staining , while HMGB1 can function both as a nuclear protein and as a secreted protein .

  • Comparing subcellular localization patterns can provide additional evidence for specific detection.

By combining these approaches, researchers can achieve high confidence in specifically detecting HMGB4 protein without cross-reactivity with other HMGB family members.